

Where can I find information on the hearing audio, legal briefs, decision and en banc appeal in connection with the MARINE patent ANDA litigation appeal at the U.S. Court of Appeals for the Federal Circuit?

The U.S. Court of Appeals for the Federal Circuit panel of three justices rendered its decision on September 3, 2020. The Court upheld the March ruling by the U.S. District Court for the District of Nevada in favor of two generic companies in connection with their abbreviated new drug applications, or ANDAs, related to Amarin's VASCEPA® (icosapent ethyl) capsule franchise. The decision is available [here](#).

On November 4, 2020, Amarin's rehearing and *en banc* petitions were denied, the court's order is available [here](#). Amarin plans to file a writ of certiorari within 90 days of such denial to ask the United States Supreme Court to hear Amarin's appeal. Amarin intends to vigorously pursue this matter but cannot predict the outcome.

Amarin filed a combined petition on October 2, 2020 for rehearing or rehearing *en banc* review of the three-justice panel decision by the full panel of 12 active justices at the Federal Circuit. The petition is available [here](#). Related developments, including the BIO brief in support of Amarin, can be found on the U.S. federal court PACER system, [here](#).

The hearing for the MARINE patent ANDA litigation oral argument at the U.S. Court of Appeals for the Federal Circuit, or Federal Circuit, occurred on September 2, 2020. An **archived recording of the argument** is posted [here](#) (search for Amarin, choose Amarin v. Hikma).

Substantive legal briefs filed with the Federal Circuit in connection with the initial appeal by parties to the litigation and *amicus curie* (friends of the court) are available through the links below:

- Amarin's opening appeal brief (May 12, 2020), [here](#)
- Amicus briefs:
 - BIO in support of Amarin (May 19, 2020), [here](#)
 - Aimed Alliance in support of Amarin (May 19, 2020), [here](#)
- Generics' response brief (June 16, 2020), [here](#)
- Amarin's reply brief (June 26, 2020), [here](#).

General information on the litigation and Amarin's policy regarding updates as the litigation and related events progress is available on the Amarin website, [here](#).

Dated: November 4, 2020